Core Viewpoint - EUDA Health Holdings Limited has amended its warrant agreement with Streeterville Capital, reducing the exercise price and minimum closing price for forced exercise, aligning with current market conditions while maintaining its long-term strategy [1][2][3] Group 1: Warrant Amendment Details - The exercise price of the warrant has been reduced from US$4.00 per share to US$2.00 per share [2] - The minimum closing price required to trigger a forced exercise has been lowered from US$6.00 to US$3.00 [2] - All other terms of the warrant remain unchanged [2] Group 2: Company Overview and Strategy - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China [3] - The company aims to address the healthcare needs of over 1.8 billion people in the region, with a strategic focus on the longevity sector [3] - EUDA is committed to transforming healthcare from reactive treatment to proactive, longevity-focused care through innovative and accessible health solutions [3]

Core Viewpoint - EUDA Health Holdings Limited has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd to support the upgrade of Shenzhen Inno's cGMP facility, enhancing EUDA's regenerative medicine capabilities in China [1][3]. Investment Details - EUDA plans to invest up to RMB 6 million in two tranches: an initial tranche of RMB 1 million and a second tranche of RMB 5 million, contingent on due diligence and regulatory approvals [2]. - The investment is structured as a convertible loan note with a 6% annual interest rate, payable semi-annually, and may be redeemed with accrued interest if not converted [4]. Facility and Technology Development - Shenzhen Inno will utilize the capital to upgrade its facility in Shenzhen, creating a state-of-the-art production and innovation center for stem cell treatments, which will serve as a core technology hub for EUDA's strategy in China [3]. - The facility will support international collaborations and provide a replicable platform for expansion into additional cities and markets [3]. Company Background - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [8]. - The company aims to lead the transformation of regional healthcare from reactive treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [8]. Strategic Vision - The CEO of EUDA emphasized that the agreement reflects a disciplined approach to building long-term stem cell therapy platforms, aiming for deeper ownership and integration over time [7].

Core Viewpoint - EUDA Health Holdings Limited has amended its warrant agreement with Streeterville Capital, reducing the exercise price and minimum closing price for forced exercise, which may enhance the attractiveness of the warrant for investors [3]. Group 1: Warrant Transaction Background - On November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital for a warrant exercisable into up to 2,000,000 newly issued ordinary shares for an aggregate purchase price of US$100,000 [2]. - The warrant was issued on December 4, 2025, and can be exercised for cash for 90 days from the issuance date, after which a cashless exercise will occur if not exercised [2]. Group 2: Amended Terms - The Warrant Amendment, effective December 16, 2025, reduces the exercise price from US$6.00 to US$4.00 per share [3]. - The minimum closing price required to trigger a "Forced Exercise" has been reduced from US$7.50 to US$6.00 [3]. Group 3: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China [4]. - The company aims to address the healthcare needs of over 1.8 billion people in the region, with a strategic focus on the growing longevity sector [4]. - EUDA is positioned to transform regional healthcare from reactive treatment to proactive, longevity-focused care [4].

Core Company Developments - EUDA Health Holdings Limited has launched a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, partnering with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital to expand its clinical and logistics network [1] - The platform represents a significant advancement in EUDA's stem cell strategy, enhancing capabilities in cell extraction, processing, cryogenic storage, logistics, and clinical application [1] Platform Design Principles - The platform is built on three core principles: centralized processing with decentralized access, long-term cell preservation for future clinical use, and integration with longevity medicine [2] Infrastructure and Capacity - Shenzhen Inno Immune Co., Ltd. serves as the primary cell processing and cryogenic storage hub in Southern China, with an initial capacity for approximately 50,000 patient cell units [3] - Wuhan Kaien Hospital is designated as the Central China clinical and longevity flagship, with a planned capacity to support around 200,000 patient cell units, integrating various health management services [4] Clinical Access and Logistics - EUDA collaborates with Guangdong Wanhai Cell Biotechnology Co., Ltd. and Shunfeng Cold Chain Logistics Co., Ltd. to establish a nationwide clinical access layer and ensure regulated transport of biological materials [6][8] - The integrated structure allows for stem cell extraction at local clinics, with subsequent processing and storage at designated facilities, ensuring quality control and scalability [8] Strategic Vision - The CEO of EUDA emphasized the transformation of regenerative medicine access in China through a coordinated national system that connects extraction, storage, logistics, and clinical delivery [9] - EUDA aims to lead the non-invasive and preventive healthcare market in Asia, addressing the healthcare needs of over 1.8 billion people in a rapidly aging population [10]

SINGAPORE, Dec. 29, 2025 (GLOBE NEWSWIRE) --  EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it will launch EUDA Helixé 2.0 in January 2026, marking the next generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixé 2.0 introduces enhancements across formulation strength, ingredient technology, delivery systems, packaging design, and ...

SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and establishment of its first clinic in Shenzhen, China. This strategic advancement builds on the Company’s earlier acquisition of distrib ...

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 100 points on Monday. The Dow rose by 0.18% to 48,222.17, the NASDAQ increased by 0.56% to 23,439.24, and the S&P 500 gained 0.45% to 6,864.96 [1] - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.81%, Hong Kong's Hang Seng up 0.43%, China's Shanghai Composite rising 0.69%, and India's BSE Sensex increasing by 0.75% [6] Sector Performance - Energy shares rose by 1.3% on Monday, while utilities stocks fell by 0.5% [1] Commodity Prices - Oil prices increased by 2.2% to $57.75, gold rose by 1.7% to $4,463.30, silver was up 2.5% to $69.150, and copper fell by 0.1% to $5.5085 [4] European Market Performance - European shares were lower, with the eurozone's STOXX 600 declining by 0.3%, Spain's IBEX 35 Index falling by 0.2%, London's FTSE 100 down by 0.5%, Germany's DAX 40 decreasing by 0.3%, and France's CAC 40 dropping by 0.5% [5] Notable Stock Movements - Haoxin Holdings Limited (NASDAQ:HXHX) shares surged by 118% to $0.7513, while Sidus Space, Inc. (NASDAQ:SIDU) increased by 78% to $2.0650 after receiving a contract from the Missile Defense Agency [8] - Jyong Biotech Ltd. (NASDAQ:MENS) shares rose by 36% to $4.32 [8] - Luminar Technologies, Inc. (NASDAQ:LAZR) shares dropped by 60% to $0.2396 after announcing voluntary Chapter 11 proceedings [8] - EUDA Health Holdings Limited (NASDAQ:EUDA) shares fell by 25% to $2.09 following a strategic technology integration announcement [8] - Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) shares decreased by 20% to $1.74 as the company announced a self tender offer [8]

Core Insights - EUDA Health Holdings Limited is integrating the QB utility token into its digital health and rewards platform, enhancing customer engagement and loyalty within its healthcare ecosystem [1][2] Group 1: Strategic Integration - The QB utility token will allow customers and agents to earn and redeem tokens for various EUDA healthcare offerings, creating a unified digital engagement platform [2] - This integration supports EUDA's long-term vision of a modern healthcare ecosystem that combines wellness, technology, and user engagement [2][5] Group 2: Technology Architecture - The integration utilizes smart contract logic to manage token issuance, vesting schedules, and ecosystem governance, ensuring secure interactions through an API layer [3] - All transactions are recorded as non-monetary exchanges, maintaining traceability within the QB ecosystem [3] Group 3: Token and Financial Structure - The QB utility token is built on Binance Smart Chain and is designed for interoperability with stablecoins like USD1, which is redeemable 1:1 with the US dollar [4] - USD1 is backed by reserves in treasury bills and cash equivalents, ensuring institutional transparency and efficiency [4] Group 4: Company Overview - EUDA Health Holdings Limited focuses on non-invasive healthcare in Asia, particularly in Singapore, Malaysia, and China, aiming to lead in the longevity sector [6] - The company addresses the healthcare needs of over 1.8 billion people in a region experiencing significant demographic shifts, with over 30% of the population aging rapidly [6]

Core Insights - Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news [1][2][3][4][5] Company Summaries - **Spyre Therapeutics, Inc. (SYRE)**: Closed at $34.71, up $1.65 or 4.99%, leading the list of gainers despite no new updates [1] - **The Oncology Institute, Inc. (TOI)**: Ended at $3.65, up $0.19 or 5.49%, with steady share price increase without new announcements [2] - **Aurora Cannabis Inc. (ACB)**: Closed at $5.70, gaining $0.13 or 2.33%, benefiting from renewed momentum in the cannabis sector [2] - **Solid Biosciences Inc. (SLDB)**: Finished at $5.45, up $0.07 or 1.30%, supported by the recent addition of Duchenne muscular dystrophy to the Recommended Uniform Screening Panel [3] - **EUDA Health Holdings Limited (EUDA)**: Closed at $2.74, gaining $0.12 or 4.58%, attracting buyers in after-hours trading [4] - **Lexeo Therapeutics, Inc. (LXEO)**: Ended at $9.50, up $0.39 or 4.28%, continuing a trend of strength in the biotech sector [4] - **Eledon Pharmaceuticals, Inc. (ELDN)**: Closed at $1.59, up $0.02 or 1.27%, managing a modest gain without new news [5]

Core Insights - EUDA Health Holdings Limited is launching an integrated digital health and rewards platform utilizing a utility cryptocurrency called QB, set to launch in January 2026 [1][2] - The QB cryptocurrency will facilitate payments, rewards, and access to EUDA's healthcare products and services, enhancing the connection between healthcare and digital finance [2][3] - This initiative aims to transform healthcare engagement into tangible economic and health benefits, promoting a unified ecosystem that combines wellness products and digital assets [3][4] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [4] - The company aims to lead the transformation from reactive medical treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [4]